These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36627145)

  • 1. New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors.
    Bamias A; Merseburger A; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36627145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
    Bamias A; Merseburger AS; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
    ESMO Open; 2021 Jun; 6(3):100152. PubMed ID: 33984672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors.
    Khaki AR; Li A; Diamantopoulos LN; Miller NJ; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Koshkin V; Park J; Alva A; Bilen MA; Stewart T; Santos V; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Shankaran V; Lyman GH; Grivas P
    Eur Urol Oncol; 2021 Jun; 4(3):464-472. PubMed ID: 33423945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced Bellmunt Risk Score for Survival Prediction in Urothelial Carcinoma Treated With Immunotherapy.
    Abuhelwa AY; Bellmunt J; Kichenadasse G; McKinnon RA; Rowland A; Sorich MJ; Hopkins AM
    Clin Genitourin Cancer; 2022 Apr; 20(2):132-138. PubMed ID: 34953754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to first-line chemotherapy regimen is associated with efficacy of ımmune checkpoint blockade therapies in patients with metastatic urothelial carcinoma.
    Tural D; Selçukbiricik F; Ölmez ÖF; Sümbül AT; Erman M; Coşkun HŞ; Artaç M; Kılıçkap S
    Int J Clin Oncol; 2022 Mar; 27(3):585-591. PubMed ID: 34762201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors.
    Sonpavde G; Manitz J; Gao C; Tayama D; Kaiser C; Hennessy D; Makari D; Gupta A; Abdullah SE; Niegisch G; Rosenberg JE; Bajorin DF; Grivas P; Apolo AB; Dreicer R; Hahn NM; Galsky MD; Necchi A; Srinivas S; Powles T; Choueiri TK; Pond GR
    J Urol; 2020 Dec; 204(6):1173-1179. PubMed ID: 32552295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
    Bellmunt J; Choueiri TK; Fougeray R; Schutz FA; Salhi Y; Winquist E; Culine S; von der Maase H; Vaughn DJ; Rosenberg JE
    J Clin Oncol; 2010 Apr; 28(11):1850-5. PubMed ID: 20231682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic model in patients with metastatic urothelial carcinoma receiving immune checkpoint inhibitors after platinum failure.
    Park JH; Park I; Kim IH; Hur JY; Hwang I; Kim C; Kim HJ; Maeng CH; Park K; Lee MY; Lee HJ; Jung JY; Keam B; Park SH; Lee JL
    Curr Probl Cancer; 2022 Jun; 46(3):100848. PubMed ID: 35344842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First-line Chemotherapy Response Is Associated With Clinical Outcome During Immune Checkpoint Inhibitor Treatment in Advanced Urothelial Carcinoma: A Real World Retrospective Study.
    Li JR; Wang SS; Lu K; Chen CS; Cheng CL; Hung SC; Chiu KY; Hsu CY; Yang CK
    Anticancer Res; 2023 Mar; 43(3):1331-1339. PubMed ID: 36854504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel immunotherapy prognostic score for patients with pretreated advanced urInary TrAct CArcinoma from the subgroup analysis of the SAUL study: the ITACA Score.
    Fornarini G; Rebuzzi SE; Buti S; Rescigno P; Merseburger A; Sternberg CN; de Giorgi U; Basso U; Maruzzo M; Giannatempo P; Ponzano M; Giunta EF; Catalano F; Murianni V; Damassi A; Cremante M; Gandini A; Puglisi S; Llaja Obispo MA; Signori A; Banna GL
    Minerva Urol Nephrol; 2023 Jun; 75(3):308-318. PubMed ID: 36511379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials.
    Alhalabi O; Hahn AW; Msaouel P; Meric-Bernstam F; Wilson N; Naing A; Piha-Paul S; Janku F; Pant S; Yap TA; Hong DS; Fu S; Karp D; Beltran K; Campbell E; Le H; Campbell MT; Shah A; Tannir NM; Siefker-Radtke A; Gao J; Roszik J; Subbiah V
    Clin Genitourin Cancer; 2022 Feb; 20(1):e16-e24. PubMed ID: 34362693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of First-line Immune Checkpoint Blockade Versus Carboplatin-based Chemotherapy for Metastatic Urothelial Cancer.
    Feld E; Harton J; Meropol NJ; Adamson BJS; Cohen A; Parikh RB; Galsky MD; Narayan V; Christodouleas J; Vaughn DJ; Hubbard RA; Mamtani R
    Eur Urol; 2019 Oct; 76(4):524-532. PubMed ID: 31362898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
    Gómez de Liaño Lista A; van Dijk N; de Velasco Oria de Rueda G; Necchi A; Lavaud P; Morales-Barrera R; Alonso Gordoa T; Maroto P; Ravaud A; Durán I; Szabados B; Castellano D; Giannatempo P; Loriot Y; Carles J; Anguera Palacios G; Lefort F; Raggi D; Gross Goupil M; Powles T; Van der Heijden MS
    Eur Urol; 2020 Feb; 77(2):269-276. PubMed ID: 31699525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
    Fornarini G; Rebuzzi SE; Banna GL; Calabrò F; Scandurra G; De Giorgi U; Masini C; Baldessari C; Naglieri E; Caserta C; Manacorda S; Maruzzo M; Milella M; Buttigliero C; Tambaro R; Ermacora P; Morelli F; Nolè F; Astolfi C; Sternberg CN
    ESMO Open; 2021 Jun; 6(3):100118. PubMed ID: 33984678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment Patterns and Attrition With Lines of Therapy for Advanced Urothelial Carcinoma in the US.
    Mathew Thomas V; Jo Y; Tripathi N; Roy S; Chigarira B; Narang A; Gebrael G; Hage Chehade C; Sayegh N; Galarza Fortuna G; Ji R; Campbell P; Li H; Agarwal N; Gupta S; Swami U
    JAMA Netw Open; 2024 May; 7(5):e249417. PubMed ID: 38696168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
    Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
    Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
    Pond GR; Agarwal A; Ornstein M; Garcia J; Gupta R; Grivas P; Drakaki A; Lee JL; Kanesvaran R; Lorenzo GD; Verolino P; Barata P; Bilen MA; Hussain SA; Curran C; Sonpavde G
    Clin Genitourin Cancer; 2021 Oct; 19(5):425-433. PubMed ID: 34006497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
    Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
    Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.